Abingdon Life Sciences, Inc. and Stason Pharmaceuticals, Inc. have extended their strategic alliance announced on August 4th, 2008. Abingdon will utilize the resources of Stason Pharma Japan Co. Ltd. to enhance their business development and IP licensing opportunities in Asia.

Abingdon will also offer strategic planning, clinical development and regulatory science support for companies in Japan and throughout Asia wishing to register pharmaceuticals, biotech products and medical devices in the United States via Stason Pharma Japan.

 "This expansion will compliment Abingdon's continued growth within the US and is a major step forward in the current economical climate. Our relationship with Stason has been beneficial for both companies and we believe this expansion will further strengthen the alliance," said Richard Lebovitz, Abingdon CEO. Hiro Hirota, President, Stason Pharma Japan added "Abingdon's strategic expansion is good news for many Japanese pharmaceutical and biotech companies who need clinical and regulatory support for their business expansion into the US market. Stason Pharma Japan will be playing an important role to develop new business opportunities between Abingdon and Asian companies, particularly in Japan."